{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:42:20Z","timestamp":1784590940419,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["1R01618"],"award-info":[{"award-number":["1R01618"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e26729","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T16:04:26Z","timestamp":1708445066000},"page":"e26729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Aubriot","family":"Anne-Sophie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-3382","authenticated-orcid":false,"given":"Morgane","family":"Penelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alv\u00e8s","family":"Cl\u00e9mence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2587-1019","authenticated-orcid":false,"given":"Silvia","family":"Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Goubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reychler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.heliyon.2024.e26729_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123603","article-title":"Immunoglobulin A mucosal immunity and altered respiratory epithelium in cystic fibrosis","volume":"10","author":"Gohy","year":"2021","journal-title":"Cells"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e26729_bib2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199212173272504","article-title":"The prognostic value of exercise testing in patients with cystic fibrosis","volume":"327","author":"Nixon","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26729_bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2017.02.007","article-title":"Peripheral muscle abnormalities in cystic fibrosis: etiology, clinical implications and response to therapeutic interventions","volume":"16","author":"Gruet","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26729_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1183\/09031936.00091607","article-title":"Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis","volume":"33","author":"Troosters","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26729_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4187\/respcare.07124","article-title":"The 1-minute sit-to-stand test in lung transplant candidates: an alternative to the 6-minute walk test","volume":"65","author":"Kohlbrenner","year":"2020","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26729_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-022-02176-6","article-title":"One-minute sit-to-stand test is practical to assess and follow the muscle weakness in cystic fibrosis","volume":"23","author":"Hardy","year":"2022","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26729_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jcf.2017.01.012","article-title":"The 1-min sit-to-stand test in cystic fibrosis - insights into cardiorespiratory responses","volume":"16","author":"Radtke","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e26729_bib8","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.4187\/respcare.04821","article-title":"The 1-minute sit-to-stand test in adults with cystic fibrosis: correlations with cardiopulmonary exercise test, 6-minute walk test, and quadriceps strength","volume":"61","author":"Gruet","year":"2016","journal-title":"Respir. Care"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26729_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246781","article-title":"Measurement properties of the one-minute sit-to-stand test in children and adolescents with cystic fibrosis: a multicenter randomized cross-over trial","volume":"16","author":"Combret","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26729_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1165\/rcmb.2006-0444OC","article-title":"Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle","volume":"40","author":"Michoud","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26729_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s004240000254","article-title":"Paucity of CFTR current but modest CFTR immunoreactivity in non-diseased human ventricle","volume":"440","author":"Du","year":"2000","journal-title":"Pflugers Arch"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26729_bib12","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.21982","article-title":"Cystic fibrosis transmembrane conductance regulator in human muscle: dysfunction causes abnormal metabolic recovery in exercise","volume":"67","author":"Lamhonwah","year":"2010","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26729_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/PEP.0000000000000086","article-title":"The effect of ivacaftor in adolescents with cystic fibrosis (G551D mutation): an exercise physiology perspective","volume":"26","author":"Saynor","year":"2014","journal-title":"Pediatr. Phys. Ther."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e26729_bib14","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1042\/CS20170995","article-title":"Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment","volume":"131","author":"Edgeworth","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.heliyon.2024.e26729_bib15","first-page":"PA2101","article-title":"The impact of Symkevi (Tezacaftor\/Ivacaftor) on exercise capacity in adolescents with CF","volume":"58","author":"Molla Imaduddin Ahmed","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e26729_bib16","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/ppul.26078","article-title":"Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis","volume":"57","author":"Causer","year":"2022","journal-title":"Pediatr. Pulmonol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26729_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J. Cyst. Fibros."},{"issue":"169","key":"10.1016\/j.heliyon.2024.e26729_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0029-2023","article-title":"G. European Cystic Fibrosis Society Exercise Working, Guidance and standard operating procedures for functional exercise testing in cystic fibrosis","volume":"32","author":"Saynor","year":"2023","journal-title":"Eur. Respir. Rev. : an official journal of the European Respiratory Society"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e26729_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049143","article-title":"Reference values and validation of the 1-minute sit-to-stand test in healthy 5-16-year-old youth: a cross-sectional study","volume":"11","author":"Haile","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e26729_bib20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00038-013-0504-z","article-title":"Population-based reference values for the 1-min sit-to-stand test","volume":"58","author":"Strassmann","year":"2013","journal-title":"Int. J. Publ. Health"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26729_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"Laboratories","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5 Pt 1","key":"10.1016\/j.heliyon.2024.e26729_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e26729_bib23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/09593985.2011.640385","article-title":"Isometric knee extension force measured using a handheld dynamometer with and without belt-stabilization","volume":"28","author":"Bohannon","year":"2012","journal-title":"Physiother. Theory Pract."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e26729_bib24","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.rmr.2013.10.645","article-title":"[Maximal isometric voluntary quadriceps strength assessment in COPD]","volume":"31","author":"Bachasson","year":"2014","journal-title":"Rev. Mal. Respir."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e26729_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.apmr.2007.07.011","article-title":"Development of a French isometric strength normative database for adults using quantitative muscle testing","volume":"88","author":"Hogrel","year":"2007","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26729_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcf.2015.08.006","article-title":"The 1-min sit-to-stand test--A simple functional capacity test in cystic fibrosis?","volume":"15","author":"Radtke","year":"2016","journal-title":"J. Cyst. Fibros."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e26729_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.heliyon.2024.e26729_bib28","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e26729_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e26729_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106073","article-title":"Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function","volume":"171","author":"Salvatore","year":"2020","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26729_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12931-020-01406-z","article-title":"Short-term effects of Lumacaftor\/Ivacaftor (Orkambi) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis","volume":"21","author":"Quon","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.heliyon.2024.e26729_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211046774","article-title":"The short-term effects of ORKAMBI (lumacaftor\/ivacaftor) on regional and distal lung structures using functional respiratory imaging","volume":"15","author":"Lauwers","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e26729_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12890-019-0866-y","article-title":"Lumacaftor\/Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction","volume":"19","author":"Wark","year":"2019","journal-title":"BMC Pulm. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e26729_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pulmoe.2022.09.009","article-title":"Changes in exercise endurance and inspiratory capacity after lumacaftor\/ivacaftor therapy in cystic fibrosis","volume":"29","author":"Savi","year":"2023","journal-title":"Pulmonology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26729_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pulmoe.2022.08.009","article-title":"Validity and reliability of the one-minute sit-to-stand test for the measurement of cardio-respiratory responses in children with cystic fibrosis","volume":"29","author":"Combret","year":"2023","journal-title":"Authors' reply, Pulmonology"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26729_bib36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e26729_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/genes14020449","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on cardiorespiratory polygraphy parameters and respiratory muscle strength in cystic fibrosis patients with severe lung disease","volume":"14","author":"Giallongo","year":"2023","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e26729_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12091421","article-title":"Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: a Short-Term Observational Case Series","volume":"12","author":"Terlizzi","year":"2022","journal-title":"J Pers Med"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024027609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024027609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:27:57Z","timestamp":1769045277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024027609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024027609"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26729","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One year effect of tezacaftor and ivacaftor on functional exercise capacity and muscle strength in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e26729"}}